Firm
The Texas-based IP litigation hires take King & Spalding’s partner appointments from pre-merger Winston & Strawn up to 12 this year
Sunny Su explains how her team overcame challenges with orchard evidence collection to secure a favourable plant variety decision from China’s top court
Flexible working firm continues trajectory from 2025 with appointment of Matthew Grant and Letao Qin
Anousha Davies, associate and trademark attorney at Birketts, unpicks how the university’s reputation enabled it to see off a proposed trademark for ‘Cambridge Rowing’
Sponsored
Sponsored
-
Sponsored by Patrinos & KilimirisMaria Kilimiris of Patrinos & Kilimiris explains how an interim ruling concerning the likelihood of confusion between Fenistil and Knistil highlights how pharmaceutical trademarks and product get-up are assessed under EU and national law -
Sponsored by RNA, Technology and IP AttorneysThere are strategic intellectual property considerations at every stage of a brand’s development. Ranjan Narula, Aditi Roy Chowdhury, and Simran Singh of RNA, Technology and IP Attorneys outline how startups can take a phased approach
-
Sponsored by Adams & AdamsMohamed Jameel Hamid and Alicia van der Walt of Adams & Adams unpack the African Continental Free Trade Area agreement, explain its impact on intellectual property, and outline practical strategies for brand owners across Africa
-
Sponsored by Cabinet M OproiuRaluca Vasilescu of Cabinet M Oproiu concludes a series on the use of artificial intelligence in patent practice by analysing how AI assistants affect the skilled reader’s perspective and the drafting of patent applications
-
Sponsored by Bird & BirdAnne-Raphaëlle Aubry of Bird & Bird explains how Section 1782 and Rule of Procedure 190 offer different pathways for cross-border evidence gathering in European patent disputes, highlighting timing, scope, and strategic considerations for litigants
-
Sponsored by Becerril, Coca & BecerrilMonica Sánchez of Becerril, Coca & Becerril explains how the Mexican intellectual property framework, including compulsory licences and the Bolar clause, works alongside emerging technologies to balance pharmaceutical innovation with public health access
